Cargando…

Second Hematopoietic Stem Cell Transplantation for Leukemia Relapsing after Myeloablative T Cell Depleted Transplants Does Not Prolong Survival

Patients with leukemia relapsing after allogeneic hematopoietic stem cell transplantation (SCT) have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsin...

Descripción completa

Detalles Bibliográficos
Autores principales:	McIver, Zachariah A., Yin, Fang, Hughes, Thomas, Battiwalla, Minoo, Ito, Sawa, Koklanaris, Eleftheria, Haggerty, Janice, Hensel, Nancy F., Barrett, A. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695054/ https://www.ncbi.nlm.nih.gov/pubmed/23524640 http://dx.doi.org/10.1038/bmt.2013.39

Ejemplares similares

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors
por: Jain, Natasha A., et al.
Publicado: (2020)

Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Jain, Natasha A., et al.
Publicado: (2014)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia
por: Carr, Anitra C., et al.
Publicado: (2020)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Pulmonary Histoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Review of the Literature
por: Natarajan, Mukil, et al.
Publicado: (2017)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2022)

Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era
por: Mussetti, Alberto, et al.
Publicado: (2015)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome
por: Chung, Yang Jo, et al.
Publicado: (2017)

Hematopoietic stem cell transplantation
por: Hatzimichael, Eleftheria, et al.
Publicado: (2010)

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia
por: Jain, Prachi, et al.
Publicado: (2017)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
por: Johnston, L, et al.
Publicado: (2011)

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Vargas, Alberto Olaya, et al.
Publicado: (2013)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
por: Bar, Merav, et al.
Publicado: (2014)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
por: Hamilton, Betty K, et al.
Publicado: (2013)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia
por: Gomyo, Ayumi, et al.
Publicado: (2020)

Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation
por: Faridi, Rehan Mujeeb, et al.
Publicado: (2016)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission
por: Walter, Roland B., et al.
Publicado: (2010)

Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Kletzel, Morris
Publicado: (2013)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

Hitting the Holy Grail of Hematopoietic Cell Transplantation with Naive T-Cell Depleted Allografts—Graft Engineered Hematopoietic Stem Cell Transplant
por: El Fakih, Riad, et al.
Publicado: (2017)

P1269: PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
por: Mata, Jonaphine, et al.
Publicado: (2023)

Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease
por: Ruiz, Milton Artur, et al.
Publicado: (2017)

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2019)

The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation
por: Oh, Suk Joong, et al.
Publicado: (2004)

Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor
por: Forlenza, Christopher J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ch1ll370kq583qh8cjrdigha45